These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 15040933)
41. Candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: developmental chemistry and investigation of immunological responses following immunization of mice and rabbits. Cox AD; Zou W; Gidney MA; Lacelle S; Plested JS; Makepeace K; Wright JC; Coull PA; Moxon ER; Richards JC Vaccine; 2005 Oct; 23(43):5045-54. PubMed ID: 16046037 [TBL] [Abstract][Full Text] [Related]
42. Structures and serology of the O-antigens of Proteus strains classified into serogroup O17 and former serogroup O35. Torzewska A; Grabowski S; Kondakova AN; Toukach FV; Senchenkova SN; Shashkov AS; Arbatsky NP; Knirel YA; Rózalski A; Kaca W Arch Immunol Ther Exp (Warsz); 2006; 54(4):277-82. PubMed ID: 16868723 [TBL] [Abstract][Full Text] [Related]
43. [Therapeutic and opsonizing effect of specific antibacterial immunoglobulins in experimental Klebsiella septicemia in mice]. Trautmann M; Fischer GI; Hahn H Immun Infekt; 1984 Feb; 12(1):56-60. PubMed ID: 6398272 [TBL] [Abstract][Full Text] [Related]
44. Molecular analysis of Shigella boydii O1 O-antigen gene cluster and its PCR typing. Tao J; Wang L; Liu D; Li Y; Bastin DA; Geng Y; Feng L Can J Microbiol; 2005 May; 51(5):387-92. PubMed ID: 16088333 [TBL] [Abstract][Full Text] [Related]
45. Structure of the O-polysaccharide of Proteus mirabilis O19 and reclassification of certain Proteus strains that were formerly classified in serogroup O19. Perepelov AV; Rózalski A; Bartodziejska B; Senchenkova SN; Knirel YA Arch Immunol Ther Exp (Warsz); 2004; 52(3):188-96. PubMed ID: 15247885 [TBL] [Abstract][Full Text] [Related]
46. Klebsiella pneumoniae lipopolysaccharide O typing: revision of prototype strains and O-group distribution among clinical isolates from different sources and countries. Hansen DS; Mestre F; Alberti S; Hernández-Allés S; Alvarez D; Doménech-Sánchez A; Gil J; Merino S; Tomás JM; Benedí VJ J Clin Microbiol; 1999 Jan; 37(1):56-62. PubMed ID: 9854064 [TBL] [Abstract][Full Text] [Related]
47. Additional O antigens of Vibrio fluvialis and Vibrio furnissii. Shimada T; Arakawa E; Okitsu T; Yamai S; Matsushita S; Kudoh Y; Okamura N Jpn J Infect Dis; 1999 Jun; 52(3):124-6. PubMed ID: 10507993 [TBL] [Abstract][Full Text] [Related]
48. Sequencing and analysis of the Escherichia coli serogroup O117, O126, and O146 O-antigen gene clusters and development of PCR assays targeting serogroup O117-, O126-, and O146-specific DNA sequences. Liu Y; DebRoy C; Fratamico P Mol Cell Probes; 2007 Aug; 21(4):295-302. PubMed ID: 17452091 [TBL] [Abstract][Full Text] [Related]
49. Passive immunotherapy of Bacillus anthracis pulmonary infection in mice with antisera produced by DNA immunization. Herrmann JE; Wang S; Zhang C; Panchal RG; Bavari S; Lyons CR; Lovchik JA; Golding B; Shiloach J; Lu S Vaccine; 2006 Jul; 24(31-32):5872-80. PubMed ID: 16790303 [TBL] [Abstract][Full Text] [Related]
50. Prevalence of serogroups and virulence factors of Escherichia coli strains isolated from pigs with postweaning diarrhoea in eastern China. Chen X; Gao S; Jiao X; Liu XF Vet Microbiol; 2004 Oct; 103(1-2):13-20. PubMed ID: 15381261 [TBL] [Abstract][Full Text] [Related]
51. Classification of Proteus mirabilis TG 115 and CCUG 10701 into the Proteus O23 serogroup based on chemical and serological studies of O-polysaccharides. Zabłotni A; Perepelov AV; Kołodziejska K; Zych K; Knirel YA; Sidorczyk Z Arch Immunol Ther Exp (Warsz); 2006; 54(6):411-7. PubMed ID: 17122881 [TBL] [Abstract][Full Text] [Related]
53. Escherichia coli O antigen typing using DNA microarrays. Liu Y; Fratamico P Mol Cell Probes; 2006; 20(3-4):239-44. PubMed ID: 16537102 [TBL] [Abstract][Full Text] [Related]
54. Identification of a second glycoform of the clinically prevalent O1 antigen from Kelly SD; Ovchinnikova OG; Müller F; Steffen M; Braun M; Sweeney RP; Kowarik M; Follador R; Lowary TL; Serventi F; Whitfield C Proc Natl Acad Sci U S A; 2023 Jul; 120(29):e2301302120. PubMed ID: 37428935 [TBL] [Abstract][Full Text] [Related]
55. Protection with bacteriophage KØ1 against fatal Klebsiella pneumoniae-induced burn wound infection in mice. Malik R; Chhibber S J Microbiol Immunol Infect; 2009 Apr; 42(2):134-40. PubMed ID: 19597645 [TBL] [Abstract][Full Text] [Related]
56. Serological characterization of the O-specific polysaccharide of Providencia alcalifaciens O23. Torzewska A; Kocharova NA; Maszewska A; Knirel YA; Rózalski A Arch Immunol Ther Exp (Warsz); 2004; 52(1):43-9. PubMed ID: 15053232 [TBL] [Abstract][Full Text] [Related]
57. Prophylaxis and therapy of Pseudomonas aeruginosa infection in cystic fibrosis and immunocompromised patients. Lang AB; Horn MP; Imboden MA; Zuercher AW Vaccine; 2004 Dec; 22 Suppl 1():S44-8. PubMed ID: 15576201 [TBL] [Abstract][Full Text] [Related]
58. DNA vaccines expressing glycoprotein complex II antigens gM and gN elicited neutralizing antibodies against multiple human cytomegalovirus (HCMV) isolates. Shen S; Wang S; Britt WJ; Lu S Vaccine; 2007 Apr; 25(17):3319-27. PubMed ID: 17287056 [TBL] [Abstract][Full Text] [Related]
59. Expansion and countrywide dissemination of ST11, ST15 and ST147 ciprofloxacin-resistant CTX-M-15-type beta-lactamase-producing Klebsiella pneumoniae epidemic clones in Hungary in 2005--the new 'MRSAs'? Damjanova I; Tóth A; Pászti J; Hajbel-Vékony G; Jakab M; Berta J; Milch H; Füzi M J Antimicrob Chemother; 2008 Nov; 62(5):978-85. PubMed ID: 18667450 [TBL] [Abstract][Full Text] [Related]
60. [Some partial antigens of uncapsulated variants of group O2 Klebsiella. IV. Content of 2a, 2c and 2e antigens in the O antigen preparations]. Kaluzewski S Med Dosw Mikrobiol; 1969; 21(1):25-36. PubMed ID: 5789982 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]